Bone density rebound in trans youth after puberty blockers

In a comprehensive meta-analysis published after searching major academic databases through September 2025, researchers examined bone density changes in transgender and gender-diverse adolescents undergoing pubertal suppression followed by gender-affirming hormone therapy. The study, which pooled data from 427 assigned-female-at-birth (AFAB) and 324 assigned-male-at-birth (AMAB) youth, found that while puberty blockers temporarily slow skeletal growth, bone mineral density partially recovers once hormone therapy begins. These findings address a critical concern flagged by clinicians: the skeletal vulnerability during this treatment window.

Slowing Down Before Catching Up

Pubertal suppression has been flagged as a time of skeletal vulnerability among transgender and gender-diverse adolescents. The review confirmed that bone growth slowed compared with peers during this phase.

Bone Density Z-Score Declines

Specifically, the meta-analysis linked puberty blocker use to temporary drops in lumbar spine z-scores, a standard measure of bone density relative to age and sex. For AFAB participants, the z-score change was -0.97 (95% CI -1.09 to -0.85), while the AMAB group showed a change of -0.73 (95% CI -0.93 to -0.53). These declines indicate that bone accrual lags behind expected rates when puberty is medically paused.

Stable Absolute Bone Density

Despite these setbacks, the absolute bone mineral density remained stable during the suppression period, meaning no actual loss of bone mass occurred—only a deceleration in expected gains. This nuance is important for understanding that the treatment does not weaken bones but rather postpones their strengthening. As the young patients later start gender-affirming hormones, the picture changes dramatically.

Rebound After Gender-Affirming Hormones

Partial Recovery of Z-Scores

Once transgender adolescents begin gender-affirming hormone therapy, bone density shows clear signs of recovery, according to the meta-analysis. At follow-up, z-scores remained numerically lower than baseline but were generally not statistically different across most skeletal sites, suggesting a catch-up effect.

Modest Gains in Absolute Density

Absolute bone mineral density increased modestly: in AFAB youth by a mean difference of 0.09 g/cm² and in AMAB youth by 0.13 g/cm². These gains, though small, indicate that the skeleton responds positively to the hormones.

The review authors concluded that puberty suppression temporarily slows bone accrual, but this is followed by a clear recovery after gender-affirming hormone therapy is initiated. This rebound was consistent enough that the initial decline can be viewed as a transient phase rather than a lasting deficit. However, the pace and extent of recovery were not uniform across all individuals, pointing to the role of personal characteristics.

Who Benefits Most? Key Influencing Factors

Factors Associated with Favorable Outcomes

The meta-regressions performed in the analysis revealed that certain factors were associated with more favorable bone density outcomes:

• Higher body mass index
• Shorter duration of GnRHa treatment
• Longer exposure to gender-affirming hormone therapy
• Older age at initiation of puberty blockers

For instance, an adolescent starting blockers at an older age and with a higher BMI might experience less pronounced z-score drops and quicker recovery. Additionally, baseline vitamin D insufficiency was common across the cohorts studied, which could compound skeletal concerns. While the study did not directly address supplementation, experts often emphasize the importance of monitoring vitamin D levels in these youth. These insights could help clinicians tailor treatment plans, such as recommending nutritional support or adjusting the timing and duration of interventions.

Reading the Findings with Caution

Study Limitations

The meta-analysis had several limitations that warrant careful interpretation:

• Relatively short follow-up periods meant that long-term bone health outcomes could not be fully assessed.
• The lack of parallel cisgender comparator groups made it difficult to isolate the exact impact of the treatments from natural variations.
• Inconsistent adjustment for key confounders.
• Sparse reporting of bone turnover markers or fracture rates, which would provide a more complete picture of skeletal integrity.

These gaps suggest that while the data points to a rebound in bone density, the evidence is not yet definitive. Future studies with longer tracking and robust control groups will be crucial to confirm these trends. In the meantime, the findings offer reassurance but should not lead to complacency.

Implications for Clinical Practice

Clinical Recommendations

For clinicians and families, the study reinforces that pubertal suppression does not irreversibly harm bone health. The temporary slowing of growth appears to be part of a dynamic process where the skeleton adapts once hormone therapy starts. However, regular monitoring of bone density and vitamin D status remains a prudent step during treatment. As always, decisions about pubertal suppression and gender-affirming care should be made in consultation with a healthcare professional who can evaluate individual risk factors.

The research, while not providing all answers, adds a vital piece to the ongoing conversation about the safety and reversibility of gender-affirming treatments in adolescence. It highlights that the body’s developmental plasticity can be harnessed to support long-term well-being, with proper medical guidance.